A comparison of chewable and regular carbamazepine (CBZ tablets) in 44 children receiving chronic CBZ monotherapy is reported from the IWK Children’s Hospital, Halifax, Nova Scotia. Weekly levels showed no consistent differences between the 1 month on chewable CBZ and on regular CBZ. Seizure control and rates of reported side effects were similar in the 2 periods. Chewable CBZ produced higher peak CBZ levels in 5 patients and a similar number had higher peaks with regular CBZ. [1]

COMMENT. Chewable and regular CBZ appear to have similar pharmacokinetics but individual patients may show some differences and those with peak level side effects using one form of CBZ should receive the alternative form of tablet.

A therapeutic bioequivalency study of brand name versus generic carbamazepine in 40 epileptic patients studied at the Bowman Gray School of Medicine, Winston-Salem, NC showed that both performed equally well in clinical efficacy and bioequivalency. [2]